Response to letter entitled: Re: ERCC3 a new ovarian cancer susceptibility gene?

Affiliations

¹ Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
² Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
³ Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain.
⁴ Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain. Electronic address: clazaro@iconcologia.net.

Comment

Agostina Stradella et al. Eur J Cancer. 2021 Jun.

. 2021 Jun:150:281-282.

doi: 10.1016/j.ejca.2021.03.015. Epub 2021 Apr 19.

¹ Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
² Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
³ Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain.
⁴ Hereditary Cancer Programme, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain. Electronic address: clazaro@iconcologia.net.

No abstract available

Conflict of interest statement

Conflict of interest statement The authors declare that there is no conflict of interest regarding the publication of this letter.

ERCC3, a new ovarian cancer susceptibility gene?
Stradella A, Del Valle J, Rofes P, Vargas-Parra G, Salinas M, González S, Montes E, López-Doriga A, Gómez C, de Cid R, Darder E, Teulé A, Solanes A, Munté E, Capellà G, Pineda M, Feliubadaló L, Brunet J, Lázaro C. Stradella A, et al. Eur J Cancer. 2020 Dec;141:1-8. doi: 10.1016/j.ejca.2020.09.023. Epub 2020 Oct 23. Eur J Cancer. 2020. PMID: 33125943
Re: ERCC3, a new ovarian cancer susceptibility gene?
Soukupova J, Zemankova P, Nehasil P, Kleibl Z; CZECANCA consortium. Soukupova J, et al. Eur J Cancer. 2021 Jun;150:278-280. doi: 10.1016/j.ejca.2021.03.014. Epub 2021 Apr 21. Eur J Cancer. 2021. PMID: 33895055 No abstract available.